New CEO Mortazavi takes UK biotech e-therapeutics into gene silencing

Pharma Phorum

UK biotech e-therapeutics has a new CEO, with executive chairman and former Silence Therapeutics chief Ali Mortazavi chosen to spearhead the next stage in the company’s development into gene silencing and other areas.

Alnylam, gene-silencing and biotech in 2020: the pharmaphorum podcast

Pharma Phorum

Alnylam’s Brendan Martin joined the pharmaphorum podcast for episode 23 to talk about his company’s work in gene-silencing and how it could offer a route to target the current coronavirus pandemic.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

A new strategy for siRNA stabilization by an artificial cationic oligosaccharide

Scienmag

Credit: TMIMS RNA interference is a gene regulatory mechanism in which the expression of specific genes is downregulated by endogenous microRNAs or by small interfering RNAs (siRNAs).

Innovate UK funding for new precision cancer treatment technology

Pharma Phorum

Programmable Oligonucleotide Delivery System (PODS), developed by Sixfold Bioscience, is a versatile system which delivers short interfering RNA (siRNA) gene silencing cargo to specific cancer cells.

Novartis’ big bet on inclisiran nears fruition, as CHMP backs drug

Pharma Phorum

If approved, inclisiran would become the first and only gene-silencing drug to reduce low-density lipoprotein cholesterol (LDL-C) in these patients.

Novartis’ big bet on inclisiran nears fruition, as CHMP backs drug

Pharma Phorum

If approved, inclisiran would become the first and only gene-silencing drug to reduce low-density lipoprotein cholesterol (LDL-C) in these patients.